Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

vopikitug

A monoclonal antibody against CD25 (IL-2R alpha), with potential antineoplastic activity. Upon administration, vopikitug targets and binds to CD25 expressed on tumor-infiltrating regulatory T (Treg) cells. This may deplete Treg cells and prevent immunosuppression, thereby enhancing anti-tumor immune responses. CD25, the alpha chain of the interleukin (IL)-2 receptor, is highly expressed on Treg cells but not on effector T (Teff) cells in tumors.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-CD25 monoclonal antibody RG6292 anti-CD25 monoclonal antibody RO7296682 T-regulatory cell-depleting antibody RO7296682
Code name:	RG 6292 RG-6292 RG6292 RO 7296682 RO-7296682 RO7296682

vopikitug

Search NCI's Drug Dictionary